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Dear Editor,
We describe a case of systemic listeriosis during a phase I
trial of ADXS11-001 (axalimogene ﬁlolisbac) in Human papil-
lomavirus (HPV)-positive oropharyngeal cancer (OPC).
ADXS11-011 is a novel therapeutic vaccine under investiga-
tion in HPV-associated malignancies.1 ADXS11-001 is a live,
bioengineered Listeria monocytogenes (Lm) vector containing a
plasmid insert (pGG55) which, inter alia, facilitates secretion of
HPV genotype-16 (HPV-16) E7 oncoprotein fused to an atten-
uated Lm virulence factor, Listeriolysin O. ADXS11-001 indu-
ces immune responses in HPV-related cancers through
multiple mechanisms of action.1,2
Clinical testing of ADXS11-001 is most advanced in cervical
cancer,1 in which HPV-16 has a causal role.3 HPV-16 is associ-
ated with other malignancies, including OPC, in which there
has recently been a rapid rise in incidence. Although HPV-
related OPC is usually cured following multi-modality treat-
ment, a not insigniﬁcant number of patients develop recurrent/
metastatic disease. In addition, current standard-of-care treat-
ments have long-term functional consequences with negative
impact on quality-of-life. Therefore, novel therapeutic agents
that will improve survival and/or reduce the incidence of
adverse events are urgently needed. Following encouraging
data from trials in cervical cancer, we initiated a dose-escalation
phase I trial of ADXS11-001 in patients treated with curative
intent for locally-advanced HPV-16-positive OPC (REALISTIC
- NCT01598792), the primary endpoint of which was to estab-
lish the safety and toxicity proﬁle of the vaccine in this clinical
setting. (https://clinicaltrials.gov).
Patient 1 was enrolled in October 2013, and received 2 vacci-
nations at dose-level 1 (3.3 £ 108 colony-forming units (CFU))
without unexpected adverse effects. Patient 2 was a 61 y old
man with a past history of treated hypertension and hypercho-
lesterolemia. He had undergone transoral laser surgery, followed
by post-operative radiotherapy, for T2N2aM0 OPC 16.5 months
previously. His ECOG performance status was 0 on trial entry.
Approximately 3.5 hours after intravenous (iv) administra-
tion of 3.3 £ 108 CFU ADXS11-001, he developed headache
and generalized ﬂu-like symptoms, although all observations
were normal. Acetaminophen (1 g) was given iv with clinical
beneﬁt. Similar symptoms, with normal observations, recurred
at 6.5 hours post-infusion and resolved with 1 g iv acetamino-
phen. At 8.5 hours post-infusion, the patient became unwell
and pyrexial (38.1C) with a tachycardia (93 bpm). Symptoms
failed to settle with further acetaminophen and he became nau-
seated and vomited. Over the next 6 hours, symptoms and vital
signs, while ﬂuctuating, were within the range expected from
previous safety data and were controlled by conservative meas-
ures (acetaminophen, ondansetron).
At 14.5 hours post-vaccination his clinical condition deterio-
rated signiﬁcantly, with pyrexia (39.1C), tachycardia (106 bpm)
and profound nausea/vomiting. At this point, per protocol, 2 g
iv ampicillin QDS and iv ﬂuids were initiated and he was trans-
ferred to the Infectious Disease Unit (IDU). Clinical examina-
tion and investigations revealed left basal pneumonia. Sequential
blood tests conﬁrmed elevated alanine aminotransferase (ALT)
and gamma glutamyl transpeptidase (xGT), peaking at 131 U/L
(NR: 7–55 U/L) and 256 U/L (NR: 0–45 U/L), respectively, on
day 7 post-vaccination. The patient’s condition improved and
he was ﬁt for discharge 7 d after admission to the IDU. Liver
enzymes returned to normal over several weeks.
Per protocol, blood was taken for culture 5 hours post-vacci-
nation and was negative for bacterial growth after 72 hours.
However, repeat blood culture, immediately before institution
of antibiotics, grew Listeria monocytogenes with identical anti-
biotic resistance to ADXS11-001 (chloramphenicol resistance
conferred by pGG55 plasmid insert). Four subsequent blood
cultures and a stool test were negative for Listeria monocyto-
genes. Chest radiograph after discharge was clear. cANCA/
pANCA were negative, Ig proﬁle was normal and there was no
paraprotein on electrophoresis. Importantly, the patient has
had no recurrence of symptoms since discharge and remains
well 20 months post-vaccination with ADXS11-001.
Following this serious adverse event, the trial was immedi-
ately put on hold. Following consultation with the vaccine
manufacturer (Advaxis), the trial was terminated early. To our
knowledge, no other cases of listeriosis have been reported fol-
lowing ADXS11-001.
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Although we did not conﬁrm sequence identity between
the pathogen grown at blood culture and ADXS11-001, the
chronology of events and pattern of antibiotic resistance
point to the fact that systemic listeriosis was caused by the
study drug. Internal review of the temperature log of the
freezer where vaccine was stored conﬁrmed several minor
temperature excursions (highest temperature ¡52C for
20 minutes) in the period before vaccination. An internal
enquiry undertaken by the sponsors and accepted by the
UK Medicines and Healthcare Regulatory Agency, found no
relationship between the temperature deviations and the
occurrence of systemic listeriosis.
In conclusion, we highlight a potential adverse event of
attenuated Lm vectors and urge caution on the part of investi-
gators working with such agents.
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